Based on our findings that APOE4 is a potent driver of HMGB1 intracellular translocation and release from neurons, we tested the therapeutic efficacy of HMGB1 inhibitors in combating APOE4-driven AD pathogenesis in the context of tauopathy. Here, HMGB1 is linked to tauopathy.